Physician profile
Kristen E Peske
NPI 1720307333
$5,085.72
in general payments reported to CMS, 2019-2025
34 companies · $788 in 2025
The $788 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $635 · 2020: $316 · 2021: $656 · 2022: $849 · 2023: $1,096 · 2024: $747 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,631.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $941.76 | 2019-2025 | Injectafer |
| Abbvie INC. | $779.27 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $614.31 | 2022-2025 | |
| Evofem Biosciences, INC. | $294.03 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $245.59 | 2019-2020 | |
| Exeltis, USA INC. | $244.81 | 2021-2025 | Slynd |
| Minerva Surgical, INC | $218.03 | 2019-2023 | |
| Coopersurgical, INC. | $161.30 | 2019-2024 | Paragard T 380a, Paragard T 380a |
| Hologic Sales and Service, LLC | $154.27 | 2019-2025 | Thinprep 2000 Processor, Aptima |
| Astellas Pharma US INC | $145.09 | 2019-2024 | Veozah, Myrbetriq |
| Organon LLC | $137.12 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $110.83 | 2019-2024 | Gardasil 9, Gardasil |
| Intuitive Surgical, INC. | $107.63 | 2025 | |
| Sumitomo Pharma America, INC. | $93.48 | 2023-2025 | Myfembree, Gemtesa |
| Ethicon US, LLC | $82.83 | 2021-2023 | Dermabond, Vistaseal, Stratafix |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $78.92 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $77.05 | 2019-2025 | |
| Sage Therapeutics, LLC | $67.73 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $67.66 | 2024 | |
| Amgen INC. | $63.95 | 2019-2025 | Evenity, Prolia, Prolia |
| Therapeuticsmd, INC. | $46.97 | 2019-2021 | |
| Avion Pharmaceuticals | $46.31 | 2020 | |
| Agile Therapeutics, INC. | $37.81 | 2021 | |
| Covidien LP | $34.75 | 2019 | |
| Mission Pharmacal Company | $32.58 | 2020-2021 | |
| Stryker Corporation | $31.12 | 2024 | Stryker |
| Pfizer INC. | $29.77 | 2020-2023 | |
| Duchesnay USA Incorporated | $29.62 | 2019 | |
| Allergan, INC. | $27.80 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $24.42 | 2021-2022 | |
| Millicent US INC | $21.93 | 2025 | Intrarosa, Femlyv |
| Myovant Sciences INC. | $20.61 | 2022 | |
| Lupin INC. | $11.48 | 2019 | |
| Meditrina | $4.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Peske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.